Low rifampicin concentrations in tuberculosis patients with HIV infection

Journal of Infection in Developing Countries

Volumn 8, Issue 8, 2014, Pages 987-993

  Gengiah, Tanuja N ^a   Botha, Julia H ^a   Soowamber, Deepak ^a   Naidoo, Kogieleum ^a   Abdool Karim, Salim S ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Discipline of Pharmaceutical Sciences School of Health Sciences University of KwaZulu Natal ^*  (United States)

Author keywords

Co infection; Drug interactions; Pharmacogenetics; Tb recurrence

Indexed keywords

ORGANIC ANION TRANSPORTER; RIFAMPICIN; SLCO1B1 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ADULT; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PLASMA; RECURRENT DISEASE; SOUTH AFRICA; TIME; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PLASMA; POLYMORPHISM, GENETIC; RECURRENCE; RIFAMPIN; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84906065910     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.4696     Document Type: Article

References (25)

1. World Health Organization. Global tuberculosis report. WHO/HTM/TB/2012.6. Available:http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf, Geneva 2012. Accessed 29 April 2013
2. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697-706.
3. Gengiah TN, Gray AL, Naidoo K, Karim QA (2011) Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 10:559-74.
4. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA (2005) Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 41: 461-469.
5. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA; AIDS Clinical Trials Group 309 Team. (2005) The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 41:1638-1647.
6. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A (2010) Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 54: 4192-4200.
7. Mitchison DA (2000) Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796-806.
8. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-279.
9. Burman WJ, Gallicano K, Peloquin C (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40: 327-341.
10. Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162: 985-992.
11. Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. The Journal of pharmacology and experimental therapeutics 304: 223-228.
12. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H (2011) The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 55: 4122-4127.
13. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118-2124.
14. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR (2007) Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 51: 2994-2996.
15. Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62: 2169-21683.
16. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS (2012) The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 68: 689-695.
17. McIlleron H, Norman J, Kanyok TP, Fourie PB, Horton J, Smith PJ (2007) Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother 60: 1398-1401.
18. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51: 3781-3788.
19. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P (2006) Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 50: 1170-1177.
20. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC (2012) Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother 56: 3232-3238.
21. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, Burger D, Nelwan RH (2002) Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 6: 497-502.
22. Klautau GB, Kuschnaroff TM (2005) Clinical forms and outcome of tuberculosis in HIV-infected patients in a tertiary hospital in Sao Paulo Brazil. Braz J Infect Dis 9: 464-478.
23. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW (2009) Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48: 1685-1694.
24. Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A, Eisenach K, Cave MD, Whalen CC, Johnson JL, Boom WH, Joloba M; Tuberculosis Research Unit (2013) Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis 17: 361-367.
25. Boeree MJ, Diacon AH, Dawson R, Venter A, du Bois J, Narunsky K, Hoelscher M, Gillespie SH, Aarnoutse RE (2013) What is the Right dose of Rifampin? Abstract# 148LB. 20th Conference on Retroviruses and Opportunistic Infections; 2013 March 3-6.; Georgia World Congress Center, Atlanta.